Serina Historical Financial Ratios

SER Stock   5.29  0.54  11.37%   
Serina Therapeutics is promptly reporting on over 77 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Invested Capital of 0.0, Average Payables of 202.4 K, Stock Based Compensation To Revenue of 0.17 or Capex To Depreciation of 0.12 will help investors to properly organize and evaluate Serina Therapeutics financial condition quickly.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Serina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.

About Serina Financial Ratios Analysis

Serina TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Serina Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Serina financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Serina Therapeutics history.

Serina Therapeutics Financial Ratios Chart

At this time, Serina Therapeutics' Days Payables Outstanding is relatively stable compared to the past year. As of 03/30/2025, EV To Operating Cash Flow is likely to grow to 0.21, while Free Cash Flow Yield is likely to drop (0.06).
Add Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D ADividend Yield
RoicPayables Turnover
RoeReturn On Tangible Assets
Earnings YieldShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Capital Employed
Fixed Asset TurnoverReturn On Assets
Asset TurnoverReturn On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Serina Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Serina Therapeutics sales, a figure that is much harder to manipulate than other Serina Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.
Most ratios from Serina Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Serina Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Serina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.At this time, Serina Therapeutics' Days Payables Outstanding is relatively stable compared to the past year. As of 03/30/2025, EV To Operating Cash Flow is likely to grow to 0.21, while Free Cash Flow Yield is likely to drop (0.06).
 2022 2023 2024 2025 (projected)
Interest Debt Per Share1.690.590.530.5
Revenue Per Share0.460.01690.01940.0184

Serina Therapeutics fundamentals Correlations

0.240.580.490.010.520.64-0.230.241.00.520.590.47-0.6-0.59-0.01-0.26-0.150.670.21-0.190.720.090.510.180.49
0.24-0.360.75-0.010.370.540.161.00.210.310.50.55-0.51-0.50.250.35-0.270.57-0.3-0.230.550.30.39-0.070.42
0.58-0.360.13-0.51-0.16-0.14-0.13-0.360.6-0.14-0.19-0.090.170.190.18-0.090.460.270.10.44-0.12-0.070.120.190.11
0.490.750.13-0.10.10.410.080.750.470.040.250.33-0.3-0.240.480.56-0.140.52-0.37-0.090.350.150.390.090.43
0.01-0.01-0.51-0.10.560.390.08-0.01-0.010.570.370.37-0.38-0.36-0.36-0.01-0.91-0.340.19-0.920.410.29-0.14-0.45-0.15
0.520.37-0.160.10.560.680.090.370.50.990.850.92-0.8-0.86-0.25-0.18-0.690.430.18-0.710.860.50.24-0.390.23
0.640.54-0.140.410.390.68-0.150.540.620.670.760.57-0.66-0.73-0.16-0.24-0.440.510.17-0.480.880.180.30.070.28
-0.230.16-0.130.080.080.09-0.150.16-0.23-0.02-0.190.340.180.20.680.49-0.310.15-0.83-0.14-0.110.65-0.34-0.76-0.23
0.241.0-0.360.75-0.010.370.540.160.210.310.50.55-0.51-0.50.250.35-0.270.57-0.3-0.230.550.30.39-0.070.42
1.00.210.60.47-0.010.50.62-0.230.210.510.570.46-0.58-0.560.0-0.26-0.120.660.21-0.170.70.090.50.180.49
0.520.31-0.140.040.570.990.67-0.020.310.510.840.87-0.79-0.85-0.38-0.26-0.670.360.31-0.720.850.450.24-0.350.21
0.590.5-0.190.250.370.850.76-0.190.50.570.840.73-0.96-0.99-0.21-0.29-0.470.610.21-0.510.90.270.630.070.61
0.470.55-0.090.330.370.920.570.340.550.460.870.73-0.68-0.740.060.16-0.620.55-0.12-0.590.730.660.18-0.530.21
-0.6-0.510.17-0.3-0.38-0.8-0.660.18-0.51-0.58-0.79-0.96-0.680.960.190.270.53-0.58-0.20.57-0.89-0.26-0.73-0.05-0.72
-0.59-0.50.19-0.24-0.36-0.86-0.730.2-0.5-0.56-0.85-0.99-0.740.960.210.290.46-0.62-0.210.5-0.91-0.2-0.59-0.07-0.58
-0.010.250.180.48-0.36-0.25-0.160.680.250.0-0.38-0.210.060.190.210.610.180.45-0.950.36-0.210.19-0.02-0.110.1
-0.260.35-0.090.56-0.01-0.18-0.240.490.35-0.26-0.26-0.290.160.270.290.61-0.12-0.06-0.640.0-0.330.29-0.26-0.35-0.18
-0.15-0.270.46-0.14-0.91-0.69-0.44-0.31-0.27-0.12-0.67-0.47-0.620.530.460.18-0.120.080.00.98-0.56-0.57-0.020.64-0.04
0.670.570.270.52-0.340.430.510.150.570.660.360.610.55-0.58-0.620.45-0.060.08-0.330.130.620.190.570.180.61
0.21-0.30.1-0.370.190.180.17-0.83-0.30.210.310.21-0.12-0.2-0.21-0.95-0.640.0-0.33-0.190.21-0.320.140.310.02
-0.19-0.230.44-0.09-0.92-0.71-0.48-0.14-0.23-0.17-0.72-0.51-0.590.570.50.360.00.980.13-0.19-0.6-0.49-0.060.55-0.05
0.720.55-0.120.350.410.860.88-0.110.550.70.850.90.73-0.89-0.91-0.21-0.33-0.560.620.21-0.60.260.49-0.040.47
0.090.3-0.070.150.290.50.180.650.30.090.450.270.66-0.26-0.20.190.29-0.570.19-0.32-0.490.260.07-0.80.12
0.510.390.120.39-0.140.240.3-0.340.390.50.240.630.18-0.73-0.59-0.02-0.26-0.020.570.14-0.060.490.070.430.99
0.18-0.070.190.09-0.45-0.390.07-0.76-0.070.18-0.350.07-0.53-0.05-0.07-0.11-0.350.640.180.310.55-0.04-0.80.430.38
0.490.420.110.43-0.150.230.28-0.230.420.490.210.610.21-0.72-0.580.1-0.18-0.040.610.02-0.050.470.120.990.38
Click cells to compare fundamentals

Serina Therapeutics Account Relationship Matchups

Serina Therapeutics fundamentals Accounts

202020212022202320242025 (projected)
Price To Sales Ratio1.1K13.842.53814.73733.25769.92
Ptb Ratio(11.37)(1.19)(0.56)21.1519.0419.99
Days Sales Outstanding34.2576.682.2K0.130.120.11
Book Value Per Share(5.04)(32.59)(35.02)0.640.730.77
Free Cash Flow Yield(0.16)(0.13)(0.0563)(0.0981)(0.0674)(0.0607)
Operating Cash Flow Per Share(7.3)(2.09)(1.92)(0.93)(0.83)(0.88)
Capex To Depreciation0.01593.250.160.110.130.12
Pb Ratio(11.37)(1.19)(0.56)21.1519.0419.99
Ev To Sales1.2K13.8345.08843.04758.73796.67
Free Cash Flow Per Share(7.32)(2.19)(1.93)(0.93)(0.83)(0.88)
Net Income Per Share(10.14)(1.17)(2.49)(1.76)(1.58)(1.66)
Research And Ddevelopement To Revenue66.331.253.154.253.823.63
Cash Per Share2.220.491.220.0410.04720.0448
Pocfratio(7.44)(18.63)(10.25)(14.83)(17.06)(17.91)
Capex To Operating Cash Flow(0.002559)(0.0482)(0.004665)(0.001284)(0.001155)(0.001213)
Pfcf Ratio(7.42)(17.78)(10.2)(14.83)(17.06)(17.91)
Days Payables Outstanding216.83353.97360.811.2K1.1K1.2K
Income Quality0.751.780.770.531.530.78
Ev To Operating Cash Flow(8.18)(18.67)(10.86)(15.35)0.20.21
Pe Ratio(5.35)(33.16)(7.93)(7.82)(8.99)(9.44)
Ev To Free Cash Flow(8.16)(17.81)(10.81)(15.35)0.20.21
Net Debt To E B I T D A(0.66)(0.0525)(0.49)(0.41)(0.47)(0.45)
Current Ratio0.433.581.250.132.42.21
Tangible Book Value Per Share(5.04)(32.59)(35.02)0.560.650.68
Receivables Turnover10.664.760.172.7K2.5K2.6K
Shareholders Equity Per Share(4.78)(32.59)(35.02)0.650.750.78
Debt To Equity(1.23)(0.0113)(0.0479)0.80.420.44
Capex Per Share0.60.01870.10.0089740.01030.009804
Graham Net Net(7.98)(33.83)(36.15)(0.74)(0.86)(0.9)
Revenue Per Share0.05042.820.460.01690.01940.0184
Interest Debt Per Share6.260.371.690.590.530.5
Debt To Assets1.60.222.110.360.03990.0379
Enterprise Value Over E B I T D A(7.31)(26.47)(8.65)(12.24)(14.08)(14.78)
Roic(11.28)(0.97)(3.75)(1.02)(1.18)(1.24)
Payables Turnover1.681.031.010.290.340.32
Roe2.120.0360.071(2.71)(3.11)(2.96)

Pair Trading with Serina Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Serina Stock

  0.54PLX Protalix BiotherapeuticsPairCorr
  0.5GE GE AerospacePairCorr
  0.44WM Waste ManagementPairCorr
  0.35LUCD Lucid DiagnosticsPairCorr
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Serina Stock Analysis

When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.